Phase 1b/2a Study | Safety, pharmacokinetics, and pharmacodynamics of Pegozafermin in patients with non-alcoholic steatohepatitis.

Safety, pharmacokinetics, and pharmacodynamics of pegozafermin in patients with non-alcoholic steatohepatitis: a randomised, double-blind, placebo-controlled, phase 1b/2a multiple-ascending-dose study – The Lancet Gastroenterology & Hepatology (link to abstract – $ for full-text)

Commentary on Twitter

New research – Loomba et al – Safety, pharmacokinetics, and pharmacodynamics of pegozafermin in patients with non-alcoholic steatohepatitis: a randomised, double-blind, placebo-controlled, phase 1b/2a study https://t.co/49u1OQKSRJ#livertwitter #NASH #fattyliver @DrLoomba pic.twitter.com/2emqc8Qkfw

— The Lancet Gastroenterology & Hepatology (@LancetGastroHep) December 13, 2022